- Continued execution on transition to a new business model from contract manufacturer to biopharmaceutical company -
- Maintained R&D focus on the development of delivery systems -
- Third quarter 2019 sales and nine-month 2019 sales respectively increased 36.9% and 28.5% vs comparative periods in 2018 -
EDMONTON, Alberta, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the three and nine-months ended September 30, 2019.
Corporate and Operational Highlights
Pipeline Development:
Technology:
Corporate:
Subsequent to Quarter:
"We are pleased with the progress we have made over the course of 2019 and the execution on our transition to a new business model from a contract manufacturer to a biopharmaceutical development company. Especially of note, we were pleased to begin trading on the OTCQX Market and believe this platform provides us with the opportunity to enhance trading liquidity, broaden our shareholder base and build significant shareholder value," commented Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro.
"On the technology front, our team has continued to focus its efforts on broadening the application and utility of our proprietary, first-in-class technologies to develop innovative delivery systems composed of new chemical complexes. By leveraging these game-changing technologies and the benefits of our two value-drivers, beta glucan and avenanthramides, we believe we are well positioned to unlock the significant opportunities to address areas of unmet need in the biopharmaceutical industry," concluded Mr. Gagnon.
Financial Highlights for the Three and Nine-Month Periods Ended September 30, 2019
CEAPRO INC. | ||
Consolidated Balance Sheets | ||
Unaudited | ||
September 30, | December 31, | |
2019 | 2018 | |
$ | $ | |
ASSETS | ||
Current Assets | ||
Cash and cash equivalents | 2,595,800 | 1,844,134 |
Trade receivables | 2,310,090 | 3,015,344 |
Other receivables | 63,653 | 46,899 |
Inventories (note 4) | 969,152 | 710,708 |
Prepaid expenses and deposits | 73,419 | 518,219 |
6,012,114 | 6,135,304 | |
Non-Current Assets | ||
Investment tax credits receivable | 607,700 | 607,700 |
Deposits | 88,340 | 88,340 |
Licences (note 5) | 22,218 | 24,440 |
Property and equipment (note 6) | 20,225,827 | 17,947,967 |
Deferred tax assets | 520,872 | 520,872 |
21,464,957 | 19,189,319 | |
TOTAL ASSETS | 27,477,071 | 25,324,623 |
LIABILITIES AND EQUITY | ||
Current Liabilities | ||
Accounts payable and accrued liabilities | 1,356,358 | 949,878 |
Current portion of long-term debt (note 7) | 162,015 | 336,956 |
Current portion of lease liabilities (note 8) | 261,680 | - |
Current portion of CAAP loan (note 10) | 80,814 | 72,942 |
1,860,867 | 1,359,776 | |
Non-Current Liabilities | ||
Long-term debt (note 7) | - | 110,350 |
Long-term lease liabilities (note 8) | 2,843,213 | - |
CAAP loan (note 10) | 129,602 | 115,216 |
Deferred tax liabilities | 524,280 | 524,280 |
3,497,095 | 749,846 | |
TOTAL LIABILITIES | 5,357,962 | 2,109,622 |
Equity | ||
Share capital (note 9 (b)) | 16,401,677 | 16,320,522 |
Contributed surplus (note 9 (e)) | 4,623,130 | 4,501,444 |
Retained earnings | 1,094,302 | 2,393,035 |
22,119,109 | 23,215,001 | |
TOTAL LIABILITIES AND EQUITY | 27,477,071 | 25,324,623 |
CEAPRO INC. | ||||||||
Consolidated Statements of Net Loss and Comprehensive Loss | ||||||||
Unaudited | ||||||||
Quarters | Nine Months | |||||||
Ended September 30, | Ended September 30, | |||||||
2019 | 2018 | 2019 | 2018 | |||||
$ | $ | $ | $ | |||||
Revenue (note 16) | 2,907,980 | 2,124,462 | 9,158,637 | 7,125,417 | ||||
Cost of goods sold | 1,894,570 | 1,057,634 | 5,327,161 | 3,403,564 | ||||
Gross margin | 1,013,410 | 1,066,828 | 3,831,476 | 3,721,853 | ||||
Research and product development | 307,477 | 997,143 | 1,919,875 | 1,995,182 | ||||
General and administration | 666,640 | 744,663 | 2,278,279 | 2,258,383 | ||||
Sales and marketing | 87,176 | 61,462 | 289,956 | 109,083 | ||||
Finance costs (note 13) | 51,865 | 15,046 | 213,052 | 101,430 | ||||
Income (loss) from operations | (99,748 | ) | (751,486 | ) | (869,686 | ) | (742,225 | ) |
Other expenses (note 12) | (3,766 | ) | (334,278 | ) | (429,047 | ) | (903,439 | ) |
Gain on settlement of royalty provisions (note 15 (c) | - | 722,895 | - | 722,895 | ||||
Loss before tax | (103,514 | ) | (362,869 | ) | (1,298,733 | ) | (922,769 | ) |
Income taxes | ||||||||
Current tax recovery | - | - | - | - | ||||
Deferred tax benefit | - | 64,200 | - | 163,200 | ||||
Income tax benefit | - | 64,200 | - | 163,200 | ||||
Total comprehensive loss for the period | (103,514 | ) | (298,669 | ) | (1,298,733 | ) | (759,569 | ) |
Net loss per common share (note 19): | ||||||||
Basic | (0.00 | ) | (0.00 | ) | (0.02 | ) | (0.01 | ) |
Diluted | (0.00 | ) | (0.00 | ) | (0.02 | ) | (0.01 | ) |
Weighted average number of common shares outstanding (note 19): | ||||||||
Basic | 77,313,015 | 76,288,921 | 77,138,854 | 75,916,828 | ||||
Diluted | 77,313,015 | 76,288,921 | 77,138,854 | 75,916,828 | ||||
The complete financial statements are available for review on SEDAR at https://www.sedar.com and on the Company's website at www.ceapro.com.
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and "active ingredients" from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit www.ceapro.com and connect with the Company on Twitter, Facebook and LinkedIn.
For more information contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: [email protected]
Issuer:
Gilles R. Gagnon, M.Sc., MBA
President & CEO
T: 780-421-4555
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
These press releases may also interest you
|